Myasthenia Gravis - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463977 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Myasthenia Gravis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H2 2019, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 6, 5, 16, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).

- The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myasthenia Gravis - Overview

Myasthenia Gravis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myasthenia Gravis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myasthenia Gravis - Companies Involved in Therapeutics Development

Ahead Therapeutics SL

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

Argenx SE

BioMarin Pharmaceutical Inc

Bristol-Myers Squibb Co

Cabaletta Bio Inc

CuraVac Inc

Grifols SA

HanAll Biopharma Co Ltd

Kashiv BioSciences LLC

Momenta Pharmaceuticals Inc

Neurotune AG

Novartis AG

Pfizer Inc

Protalex Inc

Ra Pharmaceuticals Inc

Toleranzia AB

Tolerion Inc

UCB SA

Viela Bio Inc

Myasthenia Gravis - Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amifampridine phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-1616 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

batoclimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Agonize Aryl Hydrocarbon Receptor for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bortezomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVMG-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Descartes-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efgartigimod alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBN-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inebilizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iscalimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-127 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIMS-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPL-045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPL-404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methotrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nipocalimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nomacopan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPO-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-1654 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orilanolimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06755347 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRTX-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ravulizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rozanolixizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-3034 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zilucoplan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zilucoplan XR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myasthenia Gravis - Dormant Projects

Myasthenia Gravis - Discontinued Products

Myasthenia Gravis - Product Development Milestones

Featured News & Press Releases

Oct 07, 2019: Cabaletta Bio announces presentation of preclinical data showing specific CAAR T activity against Anti-MuSK expressing B Cells

Oct 02, 2019: Ra Pharmaceuticals announces dosing of first patient in global phase 3 pivotal study of Zilucoplan for gMG

Sep 04, 2019: Ra Pharmaceuticals receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463977 | GMDHC11412IDB

Number of Pages

181

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
18-07-2017

$2,000 USD

Published by Global Markets Direct
28-02-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Myasthenia Gravis - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.